Category - Developments

Developments

Dyadic introduces novel method to produce synthetic cannabinoids

Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including...

January 21, 2022

Developments

IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial

IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...

January 20, 2022

Developments

Sigyn Therapeutics featured in BioSpace, twice

BioSpace, a leading life sciences publication, featured Sigyn Therapeutics (OTC:SIGY) and its novel extracorporeal blood purification technology twice in January. One article profiled the company and its Sigyn...

January 19, 2022

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Developments

Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy

Profound Medical (NASDAQ:PROF; TSX:PRN) treated the first patients in the Level 1 CAPTAIN trial comparing the TULSA procedure (performed with its TULSA-PRO system) against radical prostatectomy (RP). The prospective...

January 18, 2022

Developments

Absci in research collaboration with Merck

Absci (NASDAQ:ABSI), which uses deep learning AI and synthetic biology to expand the therapeutic potential of proteins, entered a research collaboration with Merck (known as MSD outside the U.S. and Canada), using...

January 7, 2022

Developments

Rencofilstat adopted as non-proprietary name for Hepion’s CRV431

Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug candidate for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases, CRV431, has been renamed, rencofilstat. The non-proprietary name change was...

January 7, 2022

Developments

Stifel sees possible rebound year for biotech; top picks for 2022

In its biotech outlook, Stifel said that “on heels of weakness and negativity, 2022 may turn out to be a rebound year wherein biotech stocks – particularly decliners despite positive results and/or commercial...

January 5, 2022

Developments

Hepion Pharmaceuticals to present clinical data at NASH-TAG conference

Dr. Todd Hobbs, CMO of Hepion Pharmaceuticals (NASDAQ:HEPA), will present data from the company’s Phase 2 AMBITION study with drug candidate, CRV431, at the NASH-TAG 2022 conference at Park City, Utah on Jan. 8...

January 5, 2022

Developments

Sigyn outlines 2021 achievements; 2022 clinical, corporate outlook

In a letter to shareholders, chairman and CEO, Jim Joyce of Sigyn Therapeutics (OTC:SIGY), said that in the face of a pandemic that paused and shuttered numerous clinical research programs, “we translated our vision for...

January 4, 2022

Category - Developments

Subscribe